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Background: Mounting evidence suggests the involvement of the dopamine system in the
pathophysiology of obsessive—compulsive disorder.
Method: The relationship of the dopamine D2 receptor (DRD2) TaqI A, and catechol-O-methyl-
transferase (COMT) NlaIII High/Low activity polymorphism to obsessive—compulsive disorder
(OCD) was examined in a sample of 150 patients and 150 controls.
Results: OCD patients did not show significant differences in genotype distribution and allele
frequency for polymorphisms investigated relative to controls. However, when the sample was
stratified by gender, there was a trend to a significant predominance of the DRD2 A2A2
genotype ( p =0.049), and a higher frequency of the DRD2 A2 allele ( p =0.020) and low-activity
COMT allele ( p =0.035) in male OCD patients compared to male controls. In addition, we
observed an association of the DRD2 A2A2 genotype in patients with an early onset of disease
(V15 years) ( p =0.033).
Conclusions: Our findings replicate previous reports and provide support for a potential role of
the COMT and DRD2 locus in subgroup of male, early onset patients with OCD.
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OCD is a common and severe, but still under-recognized,
psychiatric disorder. Family and twin studies have provided
evidence for the involvement of a genetic factor in OCD
(Nestadt et al., 2000; Pauls et al., 1995). Although very little
is known about the disorder’s pathogenesis, both serotoner-
gic and dopaminergic pathways may be implicated. A role
for dopamine in the pathophysiology of OCD is supported by
the observation that pharmacological agents enhancing
dopamine release such as methylphenidate, cocaine, and
bromocriptine may induce obsessive—compulsive symptoms
(Crum and Anthony, 1993; Jenike et al., 1990; Satel and
McDougle, 1991). In addition, evidence has accumulated
that augmentation strategies with antipsychotics are bene-
ficial for treatment-refractory OCD patients (Denys et al.,
2002; McDougle et al., 1994, 2000). Recently, SPECT studies
provided evidence for higher dopamine transporter densities
and lower dopamine D2 binding ratios in patients with OCD
relative to controls (Denys et al., 2003; Kim et al., 2003; van
der Wee et al., 2001). The combined results of these
receptor-binding studies provide circumstantial in vivo
evidence for an increased dopaminergic activity in OCD
patients.
Catechol-O-methyl transferase (COMT) is an enzyme that
has a crucial role in the elimination of dopamine. Since
COMT is involved in the inactivation of dopamine, and higher
dopamine levels may be implicated in OCD, the COMT gene
is an attractive candidate for OCD. The GYA transition in
codon 158 of the COMT gene results in a valine to
methionine substitution and is associated with a three- to
fourfold decrease in enzyme activity (valine=high-activity,
methionine=low-activity) (Lotta et al., 1995). It has already
been reported by Karayiourgou et al. (1997) that the low-
activity COMT (COMT L) allele occurs significantly more
frequently in male OCD patients, but opposing results have
also been obtained (Erdal et al., 2003; Karayiorgou et al.,
1999; Ohara et al., 1998). In addition, one might theorize
that lower densities of the D2 receptor in OCD patients are
caused by genetic factors. The A1 allele of Taq I A
polymorphism in the D2 receptor (DRD2) gene locus has
been suggested to be associated with reduced DRD2
receptor densities (Hitzemann, 1998; Jonsson et al.,
1999). Data on the DRD2 TaqI A polymorphism in OCD are
limited, but Nicolini et al. found a higher frequency of the
DRD2 TaqI A2 allele in a small subgroup of OCD patients
(n =12) with tics, when compared to controls (Nicolini et al.,
1996).
In light of the putative role of the dopamine system, and
in particular the dopamine D2 receptor in OCD, we tested
the frequency of alleles and the distribution of genotypes of
the DRD2 receptor TaqI A and of COMT genes in an OCD
sample of 150 patients. As a control population, we tested
150 ethnically matched Caucasian subjects. As there is
evidence for gender specificity of the D2 receptor and COMT
gene and because previous findings have suggested gender
differences in the clinical manifestation of OCD, males and
females were analyzed separately (Castle et al., 1995;
Kaasinen et al., 2001; Karayiorgou et al., 1999; Lensi et al.,
1996). We firstly hypothesized that OCD patients would have
higher frequencies of the COMT L allele, resulting in higher
synaptic dopamine levels. Secondly, we hypothesized thatOCD patients would have higher frequencies of the DRD2
receptor TaqI A1 allele, resulting in lower synaptic D2
receptor density.
2. Material and methods
2.1. Study sample
The patient sample comprised 159 unrelated patients with OCD
from consecutive referrals to the anxiety research unit of the
department of psychiatry at the University Medical Centre Utrecht,
who gave written informed consent for participation in this study
that had been approved by the University of Utrecht Medical Ethical
Review committee (Utrecht, The Netherlands). All patients were
diagnosed with OCD according to DSM-IV criteria and the M.I.N.I., a
clinical and structured interview, was used to confirm the diagnosis
(Sheehan et al., 1998). Severity of obsessive—compulsive symptoms
was rated with the Y-BOCS, depression with the HAM-D, and anxiety
with the HAM-A (Goodman et al., 1989; Hamilton, 1959, 1960).
Information on family history was obtained by direct interviews with
the patients and the presence of vocal and/or motor tics was
assessed during the clinical interview. The control sample was
composed of 151 ethnically matched and unrelated Caucasian
subjects, selected among healthy volunteers.
2.2. Genotyping and data analysis
Blood samples were collected from each subject and frozen at 80
8C. DNA was extracted from 10-ml samples of peripheral blood
according to standard procedures. The total number of subjects
genotyped for the genes in this study was 310. All subjects were
genotyped at the University of Ghent (Belgium) based on a coded
identification number. The COMT and DRD2 genotyping was per-
formed following a standard protocol.
2.3. COMT
For detection of the NlaIII polymorphism in codon 158, the following
oligonucleotide primers were used (5V—TCACCATCGAGATCAACCCC—
3V and 5V—ACAACGGGTCAGGCATGCA—3V) to amplify a 96-bp region
comprising the Val158Met polymorphism site. The PCR reaction was
performed under the following conditions: 94 8C for 30 s, 64 8C for 1
min, 72 8C for 1 min per cycle, for a total of 35 cycles. Digestion of 9
Al of PCR product was accomplished by incubation for 3 to 4 hours
with 5 units of NlaIII restriction enzyme at 37 8C. Digestion with
NlaIII yields either two fragments (13 bp and 83 bp) for the Val-
allele (COMT H) or three fragments (13 bp, 18 bp and 65 bp) for the
Met-allele (COMT L). The fragments were resolved on a 2.5% agarose
gel and visualized by ethidium bromide staining (Karayiorgou et al.,
1997).
2.4. DRD2
For the detection of the polymorphism in the TaqA site in the DRD2
gene the oligonucleotide primers (5V—CCGTCGACGGCTGGC-
CAAGTTGTCTA—3V and 5V—CCGTCGACCCTTCCTGAGTGTCATCA—3V)
were used to amplify a 310-bp region comprising the TaqA site
(Grandy et al., 1993). The PCR reaction was performed under the
following conditions: 94 8C for 1 min, 50 8C for 1 min, 72 8C for 1.5
min per cycle, for a total of 35 cycles. Digestion of 10 Al of PCR
product was accomplished by overnight incubation with 5 units of
TaqI restriction enzyme at 65 8C. After incubation with TaqI, the A1
allele remains intact while the A2 allele is cut into a 130-bp piece
and a 180-bp piece. The fragments resulting from the digestion
were resolved on a 1.5% agarose gel and visualized by staining with
ethidium bromide.
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Table 1 Allele frequencies and genotype distribution of the DRD2 TaqI A polymorphism
n Allele frequencies p-value Genotypes p-value
A1 A2 A1A1 A1A2 A2A2
Total sample Controls 135 0.20 0.80 0.218 5 (3.7%) 45 (33.3%) 85 (63.0%) 0.452
Patients 141 0.16 0.84 3 (3.7%) 40 (28.4%) 98 (69.5%)
Males Controls 67 0.22 0.78 0.020 2 (3.0%) 26 (38.8%) 39 (58.2%) 0.049
Patients 51 0.11 0.89 — 11 (21.6%) 40 (78.4%)
Females Controls 66 0.17 0.83 0.672 3 (4.5%) 17 (25.8%) 46 (69.7%) 0.692
Patients 88 0.19 0.81 3 (3.4%) 28 (31.8%) 57 (64.8%)
Dopamine system genes and OCD 3The association between the distribution of the genotypes and
allele frequencies with the subjects, and expected frequencies to
assess Hardy—Weinberg equilibrium, were ascertained by cross-
tabulation and v2 analysis. Considering a partial Bonferroni’s
correction, the p value for statistical significance would be 0.036
with a =0.05, 3 tests, df =2, and a correlation correction factor of
0.7.
3. Results
The patient sample was slightly skewed towards the female
population (63%) with a meanFS.D. age at admission of
36.0F11.0 years for both sexes. The mean age at onset of
obsessive—compulsive symptoms in our sample was
17.7F8.3 years, with a length of illness of 18.0F11.0 years
at entry. Males had a significantly earlier onset of illness
than females (15.7F8.0 years and 19.0F8.3 years, respec-
tively) (v2=5.85, df =1, p =0.016). The mean Y-BOCS score
for the whole sample was 24.9F5.7, with a mean HAM-D
score of 9.5F5.8 and a mean HAM-A score of 11.6F6.7.
Twenty-seven percent (43 patients) of the sample had a
first-degree relative with OCD and nine patients (6 males/3
females) reported comorbid tics at some time in their life.
The genotypic pattern of distribution and the allele
frequencies of the DRD2 and COMT polymorphisms are shown
in Tables 1 and 2. The representations of the polymorphism
of the DRD2 receptor and the COMT gene were similar in
patients and controls. No difference in frequencies of any of
the alleles was observed between patients and controls.
Both groups were in Hardy—Weinberg equilibrium at each
locus investigated.
When the sample was stratified by gender, there was a
statistically significant predominance of the DRD2 A2A2
genotype in the male patient group (v2 = 6.0, df =2,
p =0.049) and a higher frequency of the DRD2 A2 allele in
male patients compared to male controls (v2=5.4, df =2,
p =0.020). In addition, a significant association was observed
between the frequency of the COMT L allele and maleTable 2 Allele frequencies and genotype distribution of the COM
n Allele frequencies p-v
L H
Total sample Controls 152 0.51 0.49 0.6
Patients 158 0.53 0.47
Males Controls 79 0.47 0.53 0.0
Patients 56 0.60 0.40
Females Controls 71 0.56 0.44 0.2
Patients 99 0.49 0.51patients (v2=4.4, df =2, p =0.035). Although the frequency
of the COMT LL genotype was higher in male patients (37.5%)
compared to male controls (21%), the difference failed to
reach statistical significance (v2=4.6, df =2, p =0.10).
4. Discussion
The findings of this study provide evidence for an association
between the DRD2 TaqI A2 allele and the low-activity COMT
allele on the one hand, OCD on the other, in male OCD
patients.
Two previous studies have examined the association
between the DRD2 TaqI A system and OCD. Nicolini et al.
found no association in 67 patients with OCD, but observed a
higher frequency of the A2 allele in a subgroup of OCD
patients with tics (n =12) (Nicolini et al., 1996). Billet et al.
(1998) did not find an association in a sample of 100 OCD
patients either. Since the A1 allele of the DRD2 TaqI A
system has been found to be associated with a variety of
addictive, impulsive and compulsive disorders, the associa-
tion of the A2 allele with our OCD-sample was unexpected
(Comings and Blum, 2000). In addition, we presumed a
higher frequency of the A1 allele, as it has been suggested
that the A1 allele is associated with a mutation that
decreases the D2 receptor expression. This latter suggestion
has been recently confirmed by Pohjalainen et al. (1998),
but was contradicted by Laruelle et al. (1998). At the
moment, it is still unclear whether or not the Al allele is
associated with lower D2 expression (Hitzemann, 1998).
Since other reports of associations between the A2 allele
and similar neuropsychiatric disorders are scarce, the
association of the A2 allele in our sample is difficult to
interpret. The A2 allele has previously been related to
hyperactive and impulsive symptoms in attention deficit
hyperactivity disorder (ADHD) in a sample of 166 children
and to compulsive smoking habits in 793 subjects (Rowe et
al., 1999; Hamajima et al., 2002). Interestingly, the ADHDT polymorphism
alue Genotypes p-value
LL LH HH
43 39 (25.7%) 77 (50.7%) 36 (23.7%) 0.779
46 (29.1%) 75 (47.5%) 37 (23.4%)
35 17 (21.5%) 40 (50.6%) 22 (27.8%) 0.100
21 (37.5%) 25 (44.6%) 10 (17.9%)
27 21 (29.6%) 37 (52.1%) 13 (18.3%) 0.440
24 (24.2%) 49 (49.5%) 26 (26.3%)
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compulsive smoking was only significant for males. This
suggests that the A2A2 genotype of the DRD2 TaqI A system,
regardless of the diagnosis, is associated with a broad
spectrum of impulsive/compulsive symptoms in a gender
specific manner. On the other hand, without further
evidence of its functional significance, and in the absence
of other studies reporting similar associations, our finding of
the association of the A2A2 genotype and OCD in male
patients warrants replication in other samples, as well as
family-based designs.
The COMT locus has been reported to be associated with
OCD in several previous studies. Karayiorgou et al. (1997,
1999) found evidence for an association between the low-
activity COMT allele and OCD in male OCD patients, in a
case-control study and a family-based study, whereas
Alsobrook et al. (2002) found evidence pointing to an
association between the low-activity COMT allele and OCD
in female OCD patients. Niehaus et al. (2001) reported a
preponderance of COMT high/low heterozygotes in an
Afrikaner population of 54 OCD patients, but did not observe
gender differences. Schindler et al. (2000) did not find an
association between any particular allele and OCD, but
found a tendency for an association with homozygosity at
the COMT locus. Ohara et al. (1998) did not find any
association in a small sample of 24 Japanese patients and
neither did Erdal et al. (2003) in a sample of 59 Turkish
patients. A recent meta-analysis of the COMT gene in 144
OCD patients and 337 controls showed insufficient evidence
to support an association (Azzam et al., 2002).
On the other hand, since a higher prevalence of the low-
activity COMT allele in OCD patients has been established in
different independent samples, the finding of an association
between COMT and OCD remains interesting. Especially
because the results are compatible with the assumption
that increased dopamine levels are associated with obses-
sive—compulsive symptoms. It is possible that subjects with
a low-activity COMT genotype have a longer lasting and
more effective dopamine release, which makes them more
vulnerable to the development of obsessive—compulsive
symptoms. On the other hand, this is hard to reconcile with
the observation that the association is gender specific. In
this regard, it is remarkable that our results are strikingly
similar to both reports by Karayiorgou et al. (1997, 1999),
providing further evidence to the previously reported
gender-selective association between COMT polymorphism
and male patients. It is important to emphasize that in our
control sample neither the COMT genotype distribution
(v2=4.6, df =2, p =0.1), nor the allele frequency (v2=4.6,
df =2, p =0.1) differed significantly between males and
females. The significance of a gender specific association
may not be easily explained. Karayiorgou et al. (1997, 1999)
proposed that females have evolved mechanisms to com-
pensate for their lower levels of COMT activity and are
therefore less vulnerable to developing OCD in association
with a low-activity COMT genotype. On the other hand, as
has been noted by Schindler et al. (2000), the specific
association in males may be a sampling phenomenon, since
males typically demonstrate an earlier onset of OCD than
females. In our sample, males (15.7F8.0 years) had a
significantly earlier age of onset than females (19.0F8.3
years) and age of onset was significantly correlated withgender (r =0.18, p =0.033). Since only 10 out of 54 male
patients had an onset of disease later than 21 years, the bias
of age of onset cannot be excluded.
To eliminate the possible confounding factor of age of
onset, we dichotomized the patient population into an
early-onset-group (V15 years (n =60)), and a late-onset-
group (z21 years (n =45)). We found that the low-activity
COMT genotype was significantly associated with the early-
onset-group (36.7%), relative to late-onset-group (22.7%)
(v2=6.83, df =2, p =0.033), although allele frequencies did
not significantly differ (v2=0.13, df =1, p =0.71; data not
shown). Fifty-five percent of the early-onset-group was
female, which suggests that age of onset might be an
independent factor in the association with the low-activity
COMT genotype. Therefore, it is conceivable that both male
gender and early age of onset represent different subgroups
in OCD, which are independently related to the COMT gene.
Finally, some limitations of the study should be addressed.
First, case-control studies are susceptible to false positive
results due population stratification. Population stratifica-
tion may be a confounding factor in case the individuals are
selected from two genetically different populations in
different proportions in cases and controls. The risk for
population stratification in our study is limited since patients
and controls are recruited from the same geographic region
and are distributed equally. Second, although our sample is
one of largest case-control samples in OCD, our analyses are
limited and should be interpreted with caution due to the
small number of subjects.
To summarize, this study suggests that DRD2 and COMT
genes may be etiologically relevant in OCD, in a gender
specific manner, and that early-onset-patients represent a
genetically different subgroup. Further analysis of these
phenotypic subtypes in larger samples is warranted to
confirm our data.
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